Human anti-heparin-platelet factor 4 antibodies are capable of activating primate platelets: towards the development of a HIT model in primates.
In the first step to establish an animal model of heparin-induced thrombocytopenia (HIT) that is physiologically relevant to humans, studies were undertaken to determine the similarities or differences between human and non-human primate (Macaca mulatta) platelets in HIT assay systems. The collagen-, ADP-, and TRAP-induced platelet aggregation, and flow cytometric analysis of P-selectin expression and microparticle formation were similar for both species platelets (p>0.1, n=18 each). The classical HIT assays using platelet-rich plasma (PRP) as well as a flow cytometric assay revealed the activation/aggregation and serotonin release assay (SRA) profiles for both primate and human platelets were similar in response to human HIT positive sera. All assays were heparin concentration-dependent; heparin, at 0.1 U/mL, produced maximum and similar platelet activation/aggregation and SRA responses with both primate (76+/-7%, n=18) and human (68+/-11%, n=20; p>0.1) platelets. At concentrations > or =10 U/mL, heparin suppressed the platelet aggregation and SRA responses in both systems. Primate and human platelets displayed similar behavior to low molecular weight heparin and pentasaccahride in HIT assay systems. Immunoglobulins isolated from serum of patients with HIT caused activation/aggregation of human (65+/-18%, n=10 donors) and primate (79+/-12%, n=6 monkeys, p>0.08) platelets. Unlike human platelets, the primate platelets exhibited a more consistent aggregation/release response (15 out of 18 primate platelets reactive). In contrast, human donors showed wide variations in the activation/release response (4 out of 10 reactive). These observations suggest that primate platelets are activatable by anti-H-PF4 antibodies, and support the hypothesis that primates can be used to develop an animal model to study the pathogenesis of HIT.
Ahmad
S
S
Cardiovascular Institute and Departments of Pathology and Thoracic & Cardiovascular Surgery, Loyola University Chicago, Stritch School of Medicine, Maywood, IL 60153, USA.
Jeske
W P
WP
Walenga
J M
JM
Aldabbagh
A
A
Iqbal
O
O
Fareed
J
J
D000818:Animals; D001323:Autoantibodies / Q000097:blood / Q000494:pharmacology*; D001792:Blood Platelets / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D002250:Carbon Radioisotopes; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D006493:Heparin / Q000276:immunology* / Q000494:pharmacology; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood / Q000494:pharmacology; D008253:Macaca mulatta / Q000097:blood / Q000276:immunology; D019007:P-Selectin / Q000187:drug effects / Q000378:metabolism; D015539:Platelet Activation / Q000187:drug effects* / Q000276:immunology; D010974:Platelet Aggregation / Q000187:drug effects; D010978:Platelet Factor 4 / Q000276:immunology*; D011323:Primates / Q000097:blood / Q000276:immunology; D012701:Serotonin / Q000378:metabolism / Q000493:pharmacokinetics; D013921:Thrombocytopenia / Q000139:chemically induced
D001323:Autoantibodies; D002250:Carbon Radioisotopes; D007074:Immunoglobulin G; D019007:P-Selectin; D012701:Serotonin; D010978:Platelet Factor 4; D006493:Heparin